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1Tyrosinase-loaded Multicompartment Microreactor 
toward Melanoma Depletion
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ABSTRACT. Melanoma is a malignant skin cancer occurring with increasing prevalence with no 
effective treatment. A unique feature of melanoma cells is that they require higher concentrations 
of L-tyrosine (L-tyr) for expansion than normal cells. As such, it has been demonstrated that dietary 
L-tyr restriction lowers systemic L-tyr and suppresses melanoma advancement in mice. 
Unfortunately, this diet is not well tolerated by humans. An alternative approach to impede 
melanoma progression will be to administer the enzyme tyrosinase (TYR) which converts L-tyr 
into melanin. Herein, a multicompartment carrier consisting of a polymer shell entrapping 
thousands of liposomes is employed to act as a microreactor depleting L-tyr in the presence of 
melanoma cells. It is shown that the TYR enzyme can be incorporated within the liposomal 
subunits with preserved catalytic activity. Aiming to mimic the dynamic environment at the tumor 
site, L-tyr conversion is conducted by co-culturing melanoma cells and microreactors in a 
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2microfluidic set-up with applied intra-tumor shear stress. It is demonstrated that the microreactors 
are concurrently depleting L-tyr, which translates into inhibited melanoma cell growth. Thus, the 
first microreactor where the depletion of a substrate translates into anti-tumor properties in vitro 
is reported.
1. INTRODUCTION
Melanoma is currently the fifth most frequent type of cancer and the most threatening form of skin 
cancer.1 The incidence rate of melanoma has increased badly in the last century,2 and it is the cause 
of the largest part of skin cancer-related deaths.3 Despite extensive research, especially towards 
the development of targeted therapies and immunotherapies,4 current strategies have only 
demonstrated noticeable efficacy in some patients and their effect in the long-term survival is still 
variable.5 As such, newer therapeutic approaches are required for what is arguably the most 
difficult cancer to treat.5
A unique characteristic of melanoma cells is that the amino acid (AA) L-tyrosine (L-tyr) is crucial 
for their metabolic cycle and malignant melanomas require higher amounts of L-tyr to advance as 
compared to normal cells.6,7 L-tyr is an AA present in the body from protein metabolism, 
consumption of nutrients and phenylalanine hydroxylation.8 Research studies have demonstrated 
that lowering systemic levels of L-tyr using an L-tyr- and L-phenylalanine-restricted dietary intake 
can prevent the advancement of  melanoma both in vitro and in vivo.9–11 Unfortunately, low L-tyr 
diets have several drawbacks which include: a limited effect in lowering systemic L-tyr levels (to 
only ~67% of the normal levels);12 the extended treatment duration required for efficacy;8 and, 
what is worse, the fact that low L-tyr diets are not well tolerated by melanoma patients causing 
them severe adverse effects.13 Due to the associated detrimental effects, it has not been possible to 
conduct proper clinical trials by making use of restricted L-tyr diets. An alternative option to lower 
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3the amount of L-tyr needed for melanoma progression would be the use of the enzyme tyrosinase 
(TYR). TYR depletes the AA L-tyr by a series of reactions and intermediate products that result 
in the formation of melanin (Scheme 1 and Figure S1, Supporting Information).14 However, the 
administration of enzymes has some limitations and risks related to their bioavailability, toxicity, 
immune response and fast degradation upon administration.15 In particular, TYR has an 
exceptional short half-life of only about several minutes following intravenous administration.8 
This fact will involve repeated injections resulting in immunological problems and very poor 
patients compliance. Due to those challenges, the concept of treating melanoma with TYR has 
been around for some years with quite limited success.8,16,17  Research efforts towards the delivery 
of TYR for melanoma treatment include: to chemically crosslink TYR to hemoglobin (Hb) to form 
a polyHb-TYR complex16 or TYR encapsulation within polymeric capsules for oral 
administration.18 While the first approach could lower the systemic L-tyr levels to ~13% in mice, 
which translated into delayed melanoma growth,16 this procedure had several drawbacks. The 
required chemical modification of TYR to create the polyHb-TYR complex altered its catalytic 
properties. Additionally, what is worse, recent years have revealed polyHb to have important toxic 
effects due to its nitric oxide scavenging properties that result in the associated cardiovascular 
problems and higher mortality rates.19,20 In contrast, the second approach results in a more 
appropriate system for the administration of enzymes since, by making use of an encapsulation 
platform, the TYR enzyme’s structure and catalytic activity are preserved.18 However, follow up 
studies towards melanoma progression using this system both in vitro and in vivo still remain to 
be performed.
Despite the initial encouraging results, it is worth noting that these examples date back from the 
early 2000s and, thanks to the advances in materials science, recent years have spurred progress in 
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4a variety of different enzymatic micro/nanoreactors.21–23 The creation of encapsulation platforms 
entrapping enzymes protecting them from the external milieu and, thus, allowing them to conduct 
their enzymatic activity for a prolonged period of time, is envisioned to surmount the hurdles of 
enzyme delivery. The most prominent architectures able to operate as enzymatic 
micro/nanoreactors include liposomes,24 polymersomes,25,26 polymeric capsules and 
nanoparticles,27–29 and silica-based systems.30,31 Although the aforementioned structures can  
increase the applicability of enzymes by affording protection towards proteases, minimizing 
enzyme clearance while reducing their immunogenicity; it should be noted that they are all made 
of a single constituent material (i.e., lipids, polymers or silica). The exception are hybrid systems 
composed of thousands of liposomes entrapped within a polymeric carrier capsule.32,33 By 
combining these two inherently different building blocks, this multicompartment carrier exploits 
the advantages of both systems while diminishing some of their defficiencies.34–36 Liposomes are 
well suited to encapsulate fragile biomolecules such as enzymes due to their similarity to biological 
cell membranes. However, they have also some important shortcomings such as in vivo structural 
instability and scarce control over degradation.37,38 On the other hand, the polymer capsule 
overcomes the liposomes limitations by providing structural integrity and preventing liposomes 
rapid degradation.34 Importantly, the polymeric carrier shell is semi-permeable allowing the 
substrates and products to permeate in and out of the carrier, a crucial feature to perform as 
(enzymatic) microreactors in a continuous manner.
Herein we employ this multicompartment platform to encapsulate TYR and inhibit melanoma cell 
growth in vitro (Scheme 1). By using such a hybrid carrier, TYR will be entrapped within 
biomimetic liposomes avoiding misfolding or denaturation while, thanks to the polymer carrier 
shell, the liposomes will be stopped from interacting with the degrading proteases of the intra-
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5tumor environment.39 It is important to note that, in contrast to previous approaches which aimed 
to administer TYR to deplete L-tyr systemically, our multicompartment platform is envisioned to 
act as an enzyme microreactor in the tumor site following up intra-tumor administration (e.g., as 
an injectable implant).  By diminishing the amount of L-tyr substrate locally, we anticipate an 
enhanced anti-tumor effect towards melanoma progression.  
Herein, we report a new class of TYR-loaded microreactors (Scheme 1) and demonstrate their 
ability to deplete L-tyr followed by the inhibition of melanoma cells growth. In particular, we (i) 
optimize the assembly of microreactors containing different amounts of TYR-loaded liposomes, 
(ii) demonstrate that the encapsulated TYR preserves its catalytic activity by depleting L-tyr in a 
test tube, (iii) show the absence of intrinsic toxicity for the empty microreactors as well as their 
integration within melanoma cells, (iv) evaluate the potential of the as-prepared microreactors to 
inhibit melanoma cells growth in vitro both in static and in intra-tumor mimicking dynamic 
conditions.
2. EXPERIMENTAL SECTION
2.1. Materials. Triton X-100, sodium hydroxide (NaOH), hydrochloric acid, chloroform, 4-(2-
hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), dimethylchloride, bovine serum 
albumin (BSA), paraformaldehyde (PFA), Resomer® RG 502 H poly(D,L-lactic-co-glycolic acid) 
(PLGA, Mw ~12-13 kDa), poly(vinyl alcohol) (PVA, Mw ~13-23 kDa), poly(allylamine 
hydrochloride) (PAH, Mw 17.5 kDa), poly(styrenesulfonic acid sodium salt) (PSS, Mw ~77 kDa), 
tyrosinase from mushroom (TYR), L-tyrosine (L-tyr), trypsin from bovine pancreas, dimethyl 
sulfoxide (DMSO), sodium bicarbonate (NaHCO3), Phalloidin-Tetramethylrhodamine B 
isothiocyanate (Phalloidin-TRITC), 3,3'-dioctadecyloxacarbocyanine perchlorate (DiO), 
penicillin-streptomycin, sodium pyruvate, Dulbecco’s phosphate buffered saline (PBS) and 
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6Dulbecco´s Modified Eagle´s Medium-high glucose D5796 (DMEM) were purchased from 
Sigma-Aldrich (Sant Louis, MO, USA). 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC, 
phase transition temperature 24 ℃), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC, phase 
transition temperature 41 ℃) and 1-palmitoyl-2-{6-[(7-nitro-2-1,3-benzoxadiazol-4-
yl)amino]hexanoyl}-sn-glycero-3-phosphocholine (NBD-PC) were obtained from Avanti Polar 
Lipids (Alabaster, AL, USA). PrestoBlue cell viability reagent, fluorescein isothiocyanate 
(FITC) and PierceTM BCA Protein Assay Kit was obtained from Thermo Fisher Scientific 
(Waltham, MA, USA). Mus musculus skin melanoma B16-F10 (ATCC® CRL-6475™) were 
purchased from American Type Culture Collection (ATCC, USA) while RAW 264.7 cell line 
(ATCC® TIB-71™) were purchased from European Collection of Authenticated-Culture 
Collections (ECACC, UK). 
The different buffers employed were prepared with ultrapure water (Milli-Q gradient A 10 system, 
resistance 18 MV cm, TOC < 4 ppb, EMD Millipore, USA). The concentration of HEPES buffer 
was 10 mM HEPES (pH 7.4).
2.2. Enzymatic Reaction in a Test Tube. To assess the kinetics of the TYR reaction, different 
amounts of TYR (0, 4, 6, 12 and 18 U) were dissolved in either PBS or DMEM (200 µL) containing 
L-tyr (0.66 mM) and incubated at 37 ℃ for different time intervals. After the required incubation 
time, the obtained melanin product was quantified by adding NaOH (20 µL, 1M) and incubating 
for 5 h at 37 ℃ under continuous stirring. Next, the absorbance of the dissolved melanin product 
was monitored at 475 nm employing a multimode plate reader (Tecan Spark, TECAN, 
Switzerland).
2.3. Liposomes Assembly. Liposomes were fabricated according to the thin-film hydration 
method. Briefly, DMPC and DPPC at a weight ratio 7:3 were dissolved in chloroform. Following 
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7solvent removal applying vacuum over 1 h, the resulting lipid film was hydrated in HEPES buffer 
(1 mL for 2.5 mg of lipids) at 37 ˚C under constant vortexing. Upon dissolution of the lipid film, 
the resulting dispersion was extruded 11 times at 37 °C (100 nm nucleopore polycarbonate filters 
(drain disc10 mm PE, Whatman, UK) were employed). 
For fluorescently labelled liposomes (LF) 0.5 wt % of either NBD-PC (for flow cytometry and 
optimization of microreactors assembly) or DiO (to assemble microreactors for assessing their cell 
integration) was added to the lipids dissolved in chloroform. For liposomes encapsulating the TYR 
enzyme (LTYR), the lipid film was hydrated with the required units of TYR in HEPES buffer (1 
mL). To dissolve the lipid film alternating vortexing and submersion into a water bath at 42 ℃ for 
30 min was employed. After extrusion, non-encapsulated TYR was removed by dialysis using a 
300 kDa dialysis membrane (Spectrum lab, Netherlands). The as-prepared liposomes were stored 
at 4°C.
2.4. Enzyme Encapsulation. To determine the amount of TYR entrapped/associated with 
liposomes, LTYR (200 µL, 2.5 mg mL-1) were disassembled using Triton X (1% Triton X-100 in 
HEPES buffer). The amount of total enzyme was quantified by means of a bicinchoninic acid 
(BCA) assay following the commercial protocol. The encapsulation efficiency (EE) was assessed 
as described in the Supporting Information. To distinguish the amount of TYR encapsulated within 
or associated with LTYR membrane, LTYR (11 µL, 2.5 mg mL-1) were incubated in a L-tyr solution 
(200 µL, 1 M) at both 4 and 42 ℃ under continuous stirring for up to 7 days. At different time 
intervals, the samples were spun down (3 min, 8 rpm) employing a bench top centrifuge (MiniSpin, 
Eppendorf AG, Germany) and the supernatant removed. PBS (200 µL) and NaOH (20 µL, 1 M) 
were added to the supernatants and the mixture was incubated for 5 h at 37 ˚C under continuous 
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8stirring. Finally, the absorbance of the dissolved melanin product was monitored at 475 nm 
employing the Tecan Spark multimode plate reader.
2.5. Synthesis of PLGA Microspheres. PLGA microspheres were synthesized following a 
previously reported water-in-oil-in-water (w/o/w) double emulsion procedure with minor 
modifications.40 Briefly, PLGA (240 mg) was dissolved in anhydrous dichloromethane (3 mL) 
while BSA (144 mg) was dissolved in deionized water (600 µL). The mixture was emulsified with 
an ultrasonic homogenizer (150 VT Ultrasonic Homogenizer, Biologics, Inc., USA) at 50 W for 
10 s in an ice bath. The resulting emulsion was vortexed for 5 s and emulsified again for 10 s at 
50 W with the ultrasonic homogenizer. A PVA solution (4% PVA in H2O, 15 mL) was added to 
the resultant emulsion (w/o) and emulsified again by means of a homogenizer (Ultra-Turrax T25 
digital, IKA-Werke GmbH & CO., Germany) at 6000 rpm for 50 min at room temperature (RT) 
to form a double emulsion (w/o/w). For solvent extraction, the double emulsion was added to a 
PVA solution (0.4% PVA in H2O, 300 mL) and stirred magnetically at 800 rpm overnight. The 
obtained microspheres were allowed to precipitate for 4 h and were washed with deionized water 
for at least five times. 
2.6. Characterization of PLGA Microspheres. Differential interference contrast (DIC) 
microscopy images of PLGA microspheres were taken employing an Olympus microscope IX83 
(Olympus Danmark A/S, Denmark) equipped with a DIC slider and a 63× oil immersion objective. 
To assess the size of the microspheres, four independent batches were analyzed and 100 
microspheres per batch were measured by making use of the Image J software. 
2.7. Morphological Analysis of PLGA Microspheres. Surface morphology of the PLGA 
microspheres was analyzed by scanning electron microscopy (SEM) employing a FEI Quanta 200 
ESEM FEG (FEI-Company, USA). First, the microspheres were coated with gold (1.4 nm 
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9thickness) using a Q150T ES Turbo-Pumped Sputter (Quorum technologies, UK) and several 
images were taken at a working distance of 10 mm and a potential of 5 kV.
2.8. Dynamic Light Scattering (DLS) and Zeta ()-Potential. The size, polydispersity (PD) and 
-potential of liposomes and the -potential measurements of the coated PLGA microspheres at 
different steps of the assembly were assessed by adding 20 µL of a suspension of coated 
microspheres (1 × 104 microspheres µL-1) to Milli-Q water (2 mL). The measurements were carried 
out in triplicate at 25 ℃ in a ZetaPALS -potential analyzer (Brookhaven Instruments Corporation, 
USA).
2.9. Polymer Labelling. PAH was fluorescently labelled with FITC by adding a solution of FITC 
(3.7 mg in 300 µL DMSO) to a PAH solution (30 mg in 6 mL 0.05 M NaHCO3 pH 10 buffer) in 
a dropwise manner. Next, the reaction mixture was stirred overnight at RT. Next, the excess of 
FITC was thoroughly removed by two days dialysis against Milli-Q water followed by freeze-
drying to obtain PAHF.
2.10. Microreactors Assembly. A suspension of PLGA microspheres (~1 × 104 particles µL-1) 
was incubated with PAH (40 mg mL-1, 15 min) followed by 3× washes in HEPES buffer (4000 
rpm, 45 s). All centrifugation steps were conducted making use of a benchtop centrifuge 
(MiniSpin, Eppendorf AG, Germany). Up to three bilayers of alternating liposomes (either LF, 
LFTYR or LTYR) (3.6 mM, 50 min) and PAH (8 mg mL-1, 10 min) were absorbed onto the PLGA 
microspheres. Each layer deposition step was followed by 3× washes in HEPES buffer. Next, the 
carrier shell was assembled by the deposition of two bilayers of alternating PSS (1 mg mL-1, 10 
min) and PAH (8 mg mL-1, 10 min) and a final layer of PSS (1 mg mL-1, 10 min). Again, each 
layer deposition step was followed by 3× HEPES buffer washing steps. 
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10
2.11. Flow Cytometry. The number of microreactors and the fluorescence intensity of the 
microreactors entrapping LF were assessed by flow cytometry. A BD Accuri cytometer instrument 
(BD Biosciences, Sparks, USA)  and an Accuri C6 auto sampler flow cytometer plus software (BD 
Biosciences, Sparks, USA) were employed. At least two experiments were conducted 
independently and at least 20 000 events were analyzed for each experiment. The fluorescence 
intensity of the microreactors due to the encapsulated LF was measured at an excitation wavelength 
of 488 nm and a filter of 533/30 nm.   
2.12. Confocal Laser Scanning Microscopy (CLSM). Microreactors loaded with LF were 
imaged with a Leica TCS SP5 CLSM (Leica Microsystems GmbH). The CLSM was equipped 
with an Ar laser with excitation/emission wavelengths of 476/510-550 nm, respectively and a 63× 
water immersion objective. 
2.13. DIC Microscopy. An Olympus Inverted IX83 microscope was employed to take DIC images 
of the microreactors. The microscope was equipped with a 63× oil immersion objective. 
2.14. Quartz Crystal Microbalance with Dissipation Monitoring (QCM-D). A Q-sense E1 
instrument (Biolin Scientific) was employed to monitor the deposition of the different layers on a 
gold crystal (QSX301, Q-sense Biolin Scientific, Sweden). A 200 mL min-1 as flow rate was 
employed. Prior performing the measurements, the gold sensors were cleaned by exposure to 
UV/ozone for 10 min followed by immersion in a solution of Milli-Q: ammonia: hydrogen 
peroxide (5:1:1 v/v) for 5 min at 75˚C. Next, the gold sensors were rinsed with Milli-Q, dried with 
nitrogen and exposed to UV/ozone for 10 min. Next, after the HEPES baseline stabilization, a 
solution of PAH (40 mg mL-1) was loaded in the chamber reaching surface saturation. The unbound 
polymer was washed away with buffer. Next, the resulting PAH-coated surface was exposed to 
LTYR (2.5 mg mL-1) for 60 min until surface saturation was reached. The excess of LTYR was 
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11
washed away with HEPES buffer and the surface was again exposed to a PAH solution (8 mg mL-
1). Following surface saturation and rinsing with buffer, the process was repeated until three 
bilayers of LTYR-PAH were deposited onto the crystal. Finally, the surface was exposed to a PSS 
solution (1 mg mL-1) reaching surface saturation followed by washing off the PSS excess with 
HEPES buffer. The experiments were carried out at 25 ℃ and normalized frequency and 
dissipation values using the third harmonic are reported. 
2.15. Enzymatic Kinetics of Microreactors. To study the enzymatic reaction kinetics employing 
TYR-loaded microreactors, 200 µL of DMEM without phenol red containing 1 × 106 microreactors 
entrapping three LTYR layers (MR3LTYR) were incubated at 37 ℃ under continuous stirring. As 
controls, MR3LTYR at RT, free TYR at both 37 ˚C and RT, empty microreactors (MR3L) at 37 ℃ 
and DMEM only at 37 ℃ were employed. At different time points, the melanin precipitate of the 
different samples was dissolved by adjusting the pH to 11 (adding 20 µL NaOH 1M) followed by 
overnight incubation at 37 ℃. The dissolved melanin product was quantified by monitoring the 
absorbance at 475 nm employing the multimode plate reader.41
For the repeated enzymatic conversion, 1 × 106 MR3LTYR were incubated in DMEM without 
phenol red (200 µL) at 37 ℃ under continuous stirring for up to 5 days. At different time intervals, 
the samples were spun down (45 s, 4000 rpm) employing the bench top centrifuge and the 
supernatant was replaced by fresh DMEM without phenol red (200 µL). The melanin precipitate 
of the supernatants was dissolved by adjusting the pH to 11 (adding 20 µL NaOH 1M) followed 
by incubation at 37 ˚C overnight.  Next, the absorbance of the dissolved melanin product was 
monitored at 475 nm using the multimode plate reader.
2.16. Cell Experiments. Mus musculus B16-F10 melanoma cells and the macrophage RAW 264.7 
cell line were cultured in cell media consisting of DMEM supplemented with 10% (v/v) fetal 
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bovine serum (FBS), 1% (v/v) sodium pyruvate, 1% (v/v) penicillin/streptomycin (10 000 U mL-
1 and 10 µg mL-1) and 2% (v/v) HEPES at 37 °C and 5% (v/v) CO2. For cell culture, the medium 
was exchanged every two days and cells between passages three and seven (for B46-F10) and 
between passages four and six (for RAW 264.7) were used in all experiments. A cell scraper was 
employed to detach sub-confluent RAW 264.7 cells from the culture flask. For B16-F10 cells, sub-
confluent cells were detached from the culture flask by adding 3 mL trypsin. Both RAW 264.7 
and B16-F10 cells were aspirated and re-suspended in cell media. Appropriate aliquots of the as-
prepared cell suspension were added into new culture flasks. All cell experiments in the manuscript 
were conducted in triplicate. At least three independent experiments were carried out. For static 
conditions, for B16-F10, the cells were seeded  at a density of 10 000, 6000, 4000, 3000 and 2000 
cells per well for studies of 1, 2, 3, 4 and 5 days, respectively, in 300 µL of full cell media (for 
experiments performed in 96-well plates). For experiments conducted in 48-well plates, the cells 
were seeded at a density of 20 000, 12 000, 6000, 5000 and 4000 cells per well for studies of 1, 2, 
3, 4 and 5 days, respectively, in 500 µL of full cell media. For RAW 264.7, the cells were seeded 
at a density of 30 000, 15 000 and 8000 cells per well for studies of 1, 2 and 3 days, respectively, 
in 300 µL of full cell media (the experiments were conducted in 96-well plates). For dynamic 
conditions, B16-F10 melanoma cells were seeded at a density of 18 000, 11 000 and 8 000 cells in 
a closed perfusion channel (µ-slide VI0.4 six-well, ibiTreat channels, Ibidi GmbH, Munich, 
Germany) for studies of 1, 2 and 3 days, respectively, in 150 µL of full cell media. Prior adding 
the samples, the cells were allowed to attach for approximately 24 h at 37 ℃ and 5% CO2.
2.17. Microreactors Biocompatibility. Empty microreactors (MR3L) at different microreactors-
to-cell ratios (100:1 and 50:1) were added to the cells following incubation for different time 
intervals (up to 5 days) at 37 ℃ and 5% CO2. As controls, cells without microreactors exposure 
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(high control) and cell medium only (low control) were considered. After the different incubation 
times, the cells were washed 2× in PBS (200 µL) and 1× in a mixture of DMEM and PrestoBlue® 
cell viability reagent (90 µL DMEM + 10 µL PrestoBlue®). Next, the mixture of DMEM and 
PrestoBlue® cell viability reagent was added to the different wells and incubated for 1 h at 37 ˚C 
in the dark. Finally, the fluorescence intensity of the reduced resazurin product was assessed at 
excitation/emission wavelength of 535/615 nm using the multimodal plate reader. The normalized 
cell viability was calculated as follows: normalized cell viability (%)  (experimental value – low 
control value)/(high control value – low control value) × 100. 
2.18. Microreactors Integration within B16-F10 Melanoma Cells. Sterile cover glasses were 
placed in the different wells of 48-well plates. Next, the B16-F10 cells were seeded either in the 
48-well plates (static conditions) or in the channels of the microfluidic set up (dynamic conditions). 
Following 24 h of cell attachment, TYR-loaded microreactors either assembled employing PAHF 
(MR3LTYR-PAHF) or LFTYR (MR3LFTYR) were added at a microreactors-to-cell ratio 50:1 were 
added to the wells (static conditions) or to the channels (dynamic conditions). For dynamic 
conditions, the syringes of the pump system (loaded with 7.5 mL of complete cell media) were 
connected to the channels. The Ibidi Pump System (Ibidi GmbH, Germany) was used to apply two 
different controlled shear stresses ( = 0.5 dyn cm-2 (τ0.5) and  = 20 dyn cm-2 (τ20)) for different 
time intervals.  The cells were then incubated at different time-points at 37 ℃ and 5% CO2. As 
controls, cells without microreactors exposure at both τ0.5 and τ20 for dynamic conditions and at 
τ0 for static conditions, were considered. After the different incubation times, the cells from either 
the wells or the channels were washed in PBS 2× to remove the loosely bound microreactors and 
fixed using a 4% PFA solution in PBS for 30 min. Next, the cells were washed in PBS 3×. For 
staining, the cells were first permeabilized using T-PBS (0.1% Triton X-100 in PBS) for 15 min. 
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A BSA solution (2% BSA in PBS) for 2 h was used to block the nonspecific points. Incubation of 
the cells in a solution of phalloidin-TRITC (0.1 µg mL-1 in PBS) for 1 h at RT in the dark was used 
to stain the actin filaments. The cells in the wells or in the channels were then washed 3× in PBS 
and imaged by CLSM (Leica Microsystems GmbH, Wetzlar, Germany). A DPSS 561 laser with 
emission/excitation wavelength 561/565-670 nm was used for phalloidin-TRITC detection while 
an Ar laser with emission/excitation wavelength 488/495-505 nm was employed for both 
MR3LTYR-PAHF and MR3LFTYR detection. A 63× water immersion objective was employed.
2.19. Inhibition of Melanoma Cells Proliferation. For static conditions, B16-F10 and RAW 
264.7 cells were seeded onto 96-well plates (static conditions) and to the channels of the 
microfluidic chamber (dynamic conditions). After 24 h incubation, the cells were washed in PBS 
(2×) and MR3LTYR at 50:1 microreactors-to-cell ratio were added to the wells and channels. For 
dynamic conditions, the syringes of the pump system (loaded with 7.5 mL of complete cell media) 
were connected to the channels. The Ibidi Pump System was used to apply two different controlled 
shear stresses (0.5 and τ20). The cells were incubated for different time intervals (up to three 
days) at 37 ℃ and 5% CO2. As controls, for both static and dynamic conditions, free TYR and 
cells without microreactors exposure were considered. Cells without microreactors exposure at 0 
was considered as the high control while medium only at 0 was considered as the low control. 
After the different incubation times, the cells from both the wells and the channels were washed 
2× in PBS (200 µL for wells and 100 µL for channels) and 1× in fresh DMEM (90 µL for both 
wells and channels) containing PrestoBlue® cell viability reagent (10 µL for both wells and 
channels). Next, fresh DMEM (90 µL for both wells and channels) containing PrestoBlue® cell 
viability reagent (10 µL for wells and channels) was added to the different wells/channels and 
incubated for 1 h at 37 ˚C in the dark. The fluorescence intensity of the reduced resazurin product 
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was assessed at excitation/emission wavelength of 535/615 nm using the multimodal plate reader. 
The normalized cell viability was calculated as follows: normalized cell viability (%) 
 (experimental value – low control value)/(high control value – low control value) × 100. 
2.20. Statistics. A Tukey´s multiple comparison posthoc test (n=3; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 
0.001; ****p ≤ 0.0001) was employed using a GraphPad Prism 7 software to assess the statistical 
differences between the different conditions. A one-way ANOVA with a confidence level of 95% 
(α = 0.05) was employed.
3. RESULTS AND DISCUSSION
3.1. Enzymatic Conversion Using Free TYR in Solution. As a first step, we aimed to illustrate 
that the activity of the enzymatic reaction could be monitored. TYR catalyzes the conversion of L-
tyr into melanin by a series of reactions (Figure S1, Supporting Information).42  To this end, we 
incubated different amounts of TYR in a L-tyr solution (0.66 mM in PBS) at 37 ˚C and quantified 
the amount of melanin formed at different time-points. The melanin precipitate was dissolved and 
the absorbance of the disintegrated product was measured at 475 nm (Figure S2a, Supporting 
Information).43,44 Our ultimate goal is to conduct the enzymatic conversion of L-tyr in the presence 
of melanoma cells. Therefore, we also monitored the kinetics of the TYR reaction in Dulbecco´s 
Modified Eagle´s Medium (DMEM) without the addition of phenol red. As expected, no 
differences in the kinetics of the enzymatic reaction were observed (Figure S2b, Supporting 
Information).
3.2. Assembly Optimization for TYR-Loaded Microreactors.  3.2.1. Liposomes Assembly and 
Characterization. The first step to assemble advanced microreactors involves enzyme 
encapsulation within liposomes. Liposomes are excellent candidates to entrap delicate 
biomolecules such as enzymes, preventing them from denaturation, by means of their lipid bilayer 
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membrane which resembles the membrane of biological cells.37,38 Since our multicompartment 
microreactors have as a goal depleting L-tyr inside the human body, we assembled TYR-loaded 
liposomes (LTYR) that operate close to physiological temperature (~37 ˚C). As such, LTYR were 
constituted by a lipid mixture displaying a liquid-to-gel phase transition temperature (Tm) close to 
37 ˚C. In particular, we employed 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC, Tm ~24 
⁰C) and 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC, Tm ~41 ⁰C) in a 7:3 weight ratio. 
At low temperatures such as room temperature (RT, ~23 ⁰C < Tm), LTYR offer an effective barrier 
for small molecules while, upon rising the temperature to or above the Tm, L-tyr can permeate 
through the lipid bilayer and interact with the entrapped TYR enzyme (Scheme 1a). Following on, 
to fabricate microreactors with high enzymatic activity, we evaluated the highest amount of TYR 
that could be encapsulated or associated with the liposomes. We assembled LTYR by hydrating the 
lipid film with different amounts of TYR. After removing the non-encapsulated/associated TYR 
by dialysis, the total amount of TYR was evaluated by rupturing the liposomes with Triton-X 
followed by a bicinchoninic acid (BCA) assay. Figure 1a shows a maximum experimental TYR 
concentration of ~750 µg mL-1 (or 2015 U) when LTYR are constituted by 2.5 mg mL-1 lipids. This 
loading was achieved when hydrating the lipid film with 1 mL of a 1116 µg mL-1 TYR solution in 
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (HEPES) buffer. LTYR had a diameter of 
166.6  6.4 nm and a surface charge of -21.4  2.9 mV, respectively, as shown by dynamic light 
scattering (DLS) and zeta (ζ)-potential measurements (Figure 1b and c). Barely any change in the 
liposomes diameter was observed for LTYR vs empty L. In contrast, an increase in negative ζ-
potential is observed for LTYR upon increasing the TYR concentration (until reaching saturation 
conditions), which we attribute to the negatively charged nature of TYR at physiological pH 
(Figure 1c). 
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To discern between the amount of TYR encapsulated from the TYR associated with the liposomes 
membrane, we evaluated the enzymatic conversion at temperatures below (4 ˚C) and above (42 
˚C) the Tm of the liposomes. At 4 ˚C the liposomes membrane is in the “gel state” and, thus, L-tyr 
can only react with the TYR enzyme attached to the liposomes membrane. In contrast, at 42 ˚C 
the liposomes membrane is in the “liquid state” making possible for L-tyr to cross the lipid bilayer 
and interact with the entrapped TYR. The enzymatic kinetics, which have been normalized to the 
highest absorbance reading, were conducted until a reaction end point was reached for at least 
three days. The results suggest ~40% of TYR encapsulation (Figure 1d). It is worth noticing that 
no difference in TYR kinetics was observed when the enzymatic reaction was conducted for the 
free TYR at different temperatures (Figure S3, Supporting Information).  
3.2.2. Optimization of Microreactors Assembly. As an advanced microreactor able to deplete L-tyr 
in the intra-tumor environment, we chose a multicompartment carrier composed by intact 
liposomes entrapped within a protective polymeric shell. We,36,45 and others,46–48 have reported 
the assembly of such a multicompartment carrier based on the layer-by-layer (LbL) technique. The 
LbL technique entails the alternating deposition of interacting compounds (e.g., polymers and 
liposomes) onto a (sacrificial) core. Those microreactors have been mainly assembled by 
employing silica particles as a (sacrificial) core template and either biodegradable disulfide 
crosslinked poly(methacrylate)36,45 or polydopamine35,46–50 as the constituents of the carrier shell. 
In contrast, herein, with the aim to obtain microreactors that are able to conduct their function for 
an extended period of time, we employ a non-degradable polymer pair. To construct the carrier 
shell we make use of poly(allylamine hydrochloride) (PAH) and poly(styrene sulfonate) (PSS) 
which interact by electrostatics (Schematic 2).32 Additionally, since our goal is to fabricate an 
extracellularly active microreactor, to minimize or even eliminate the microreactors uptake by 
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melanoma cells, we assembled microreactors without removing the core template. With that in 
mind, we chose as a core micron-sized biocompatible poly(D,L-lactide-co-glycolide) (PLGA) 
microspheres fabricated by a double emulsion process.41 The as-prepared PLGA microspheres 
displayed a size ranging from 1 to 9 µm in diameter with the highest amount of microspheres 
exhibiting a diameter between 3 to 6 µm. As shown by scanning electron microscopy (SEM) 
images (Figure S4, Supporting Information) the microspheres display a uniform, smooth structure 
without the presence of large pores. Next, we assembled the microreactors by depositing alternate 
layers of PAH, PSS and LTYR. The combination of PSS and PAH was chosen to assemble the 
polymeric shell since this polymer pair is widely known to yield non-aggregated and structurally 
stable particles and capsules.51,52 Additionally, the non-degradable nature of this polymer pair will 
render microreactors with good structural integrity for prolonged time periods. 
To optimize the microreactors assembly, we first characterized the adsorption of LTYR onto PLGA 
microspheres. To render a positively charged surface that allows for LTYR immobilization, the 
PLGA microspheres were first coated by a PAH layer. We first established the amount of PAH 
needed to revert the charge of the PLGA microspheres. We monitored the ζ-potentials of the 
microspheres upon incubation with different PAH concentrations for different time intervals. As 
expected, the higher the PAH concentration, the higher the ζ-potentials until saturation was 
reached for a 40 mg mL-1 PAH solution (Figure 2a). An additional increase in PAH concentration 
did not translate into a notable increase in ζ-potential. Following on, after LTYR deposition, we 
optimized the LbL growth for a polymeric shell constituted by PAH and PSS. PSS and PAH were 
chosen due to prior history in yielding non-aggregated and structurally stable particles and 
capsules.51,52 We monitored the ζ-potential of the microspheres as a function of both the number 
of PAH and PSS layers and their concentrations (Figure 2b). Upon deposition of a PAH precursor 
Page 18 of 53
ACS Paragon Plus Environment
ACS Applied Materials & Interfaces
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
19
layer, the ζ-potential of the PLGA microspheres increased by ~85 mV. We attribute this sharp 
increase in ζ-potential to the porous nature of the PLGA microspheres. When LTYR were adsorbed, 
a ~60 mV decrease in ζ-potential was observed due to the overall negative charge of LTYR. Next, 
4 mg mL-1 concentrations of both PAH and PSS were employed to assemble the shell of the 
multicompartment carrier. The ζ-potential of the microspheres alternated between +5 mV and -60 
mV when PAH and PSS formed the outer layer, respectively (Figure 2bi). Such a switch in the 
sign of the ζ-potential are distinctive of the LbL formation of multilayers on colloids and suggest 
a step-wise layer growth of PAH and PSS.53  We next aimed to obtain ζ-potential measurements 
closer to the values that are usually obtained for PAH and PSS (~+30 mV and ~-20 mV for PAH 
and PSS as outermost layer, respectively).54 Thus, we assessed the ζ-potential of the coated-PLGA 
microspheres for different PAH and PSS concentrations. We first decreased the PSS concentration 
to 1 mg mL-1 while maintaining the PAH concentration constant (4 mg mL-1). This resulted in a ζ-
potential alternating between ~+2-3 mV and ~-40 mV for PAH and PSS as the outer layer, 
respectively (Figure 2bii). Next, to achieve a higher ζ-potential upon PAH deposition, we increased 
the PAH concentration to 8 mg mL-1. The results show ζ-potential measurements ranging from 
~+30 mV to ~-30 mV, which are values closer to the ones reported in literature,54 thus promoting 
a good surface coverage (Figure 2biii).
Next, to maximize the number of liposomal compartments and consequently the quantity of 
entrapped TYR, we identified the upper limit of liposome multi-layering onto PAH-coated PLGA 
microspheres. We monitored the adsorption of fluorescently labelled LTYR (LFTYR) onto PAH-
coated PLGA microspheres by flow cytometry. Figure 3 shows fluorescence intensity (FI) 
readings for PAH and LFTYR deposition onto PLGA microspheres. The readings are normalized to 
the first LFTYR deposition step (nFI), which was set to 100% and assigned as a single liposome 
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layer. After the first LFTYR deposition step, to allow for the adsorption of a second LFTYR layer, the 
deposition of a separation polymer layer is required. To reverse the charge of the coated 
microspheres, positively charged PAH was adsorbed. This PAH separation layer between LFTYR 
supported the addition of three extra LFTYR deposition steps. While the second deposition step 
allowed for the adsorption of ~2.5 LFTYR layers, the third and fourth liposome deposition steps 
supported the addition of almost 3 and ~1.2 LFTYR layers, respectively. After four liposome 
deposition steps, any additional exposure of the colloids to LFTYR promoted aggregation of the 
coated microspheres. The stability of LFTYR during subsequent carrier shell assembly was also 
investigated for the four different scenarios (i.e., one, two, three and four LFTYR deposition steps). 
The FI readings, which have been normalized to the first LFTYR deposition step, show no notable 
loss in nFI during subsequent PAH/PSS layering for any of the tested conditions (Figure 4a i-iv). 
The microreactors assembled with different LFTYR deposition steps were visualized using 
differential interference contrast (DIC) and fluorescence microscopy to corroborate and analyze 
their appearance and structural integrity (Figure 4b). Fluorescence microscopy images showed that 
the LFTYR were homogeneously distributed around the PLGA microspheres as shown by the 
homogeneous fluorescence signal. They also confirmed the presence of additional LFTYR layers for 
microreactors assembled by increasing number of liposome deposition steps, as shown by the 
increasing fluorescence intensity signal. The microscopy images also demonstrated that, while 
microreactors prepared by one, two or three LFTYR deposition steps where intact and non-
agglomerated, the microspheres aggregated for microreactors with four LFTYR-deposition steps 
(Figure S5, Supporting Information, shows enlarged microscopy images). Hence, only 
microspheres loaded with three LFTYR deposition steps (MR3LTYR) where considered for the next 
experiments.
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Despite the encouraging results, the flow cytometry data together with the fluorescence 
microscopy images, only proved the presence of fluorescently labelled lipids linked to the 
microspheres. Only the combination with quartz crystal microbalance with dissipation monitoring 
(QCM-D) measurements will verify the presence of structurally intact LTYR (Figure 5). In good 
agreement with the data attained by flow cytometry on PLGA microspheres, the adsorption of 
PAH precursor polymer layer onto gold sensors was corroborated by assessing the change of 
frequency (Δf) of -6.55  0.25 Hz. This positively charged surface allowed for the adsorption of 
negatively charged LTYR as shown by the Δf of -111.71  22.01 Hz. The change in dissipation 
(D) of 30.90 × 106  9.32 × 106, suggests the deposition of intact liposomes rather than a 
supported lipid bilayer.55 Next, a PAH separation layer, as confirmed by a f of -18.38  6.50 Hz, 
was adsorbed to allow for the deposition of additional LTYR. The successful deposition of intact 
liposomes was also confirmed by the large f and D (of –71.86  1.00 Hz and 28.66 × 106  0.91 
× 106 for f and D, respectively). After addition of the second PAH separation layer (f of –
18.21  2.54 Hz) a third deposition step of intact LTYR was successfully adsorbed as shown by a 
f of –123.25  19.21 Hz and a D of 29.56 × 106  1.78 × 106, which again are in the envisioned 
range for the incorporation of intact liposomes. The adsorption of PAH and PSS to assemble the 
microreactors shell was corroborated without rupture or rearrangement of the underlying 
liposomes as shown by the film growth (PAH, f of –29.72  8.92 Hz and D of 6.84 × 106  2.30 
× 106; PSS, f of –25.46  3.24 Hz and D of 9.73 × 106  6.43 × 106).
3.3. Microreactors Functionality. 3.3.1. Kinetics of the Enzymatic Reaction. To evaluate the 
MR3LTYR’s potential as an intra-tumor microreactor for the depletion of L-tyr, we incubated 
MR3LTYR at 37 ℃ in a DMEM solution without the addition of extra L-tyr. The kinetics of the 
enzymatic conversion of L-tyr by MR3LTYR were normalized to the highest absorbance reading 
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(nAbsorbance). The kinetics of MR3LTYR at 37 ℃ were compared to the kinetics of MR3LTYR at 
RT, same amounts of TYR enzyme in its free form (as determined by a calibration curve), empty 
microreactors (MR3L) and DMEM only. Enzymatic conversion was only observed for MR3LTYR 
and free TYR, where the absorbance measurements steadily increased for the first hours levelling 
off after one day of reaction (Figure 6a). While, for both MR3LTYR at 37 ℃ and free TYR (at 37 ℃ 
and RT), the enzymatic processes took place at a similar rate, the results were different for 
MR3LTYR at RT. In agreement with the results of Figure 1d, which demonstrated that ~40% of 
TYR was encapsulated inside LTYR, the nAbsorbance readings for MR3LTYR at RT are ~40% lower 
than for MR3LTYR at 37 ℃. This result again demonstrates that at RT (temperature < Tm), L-tyr 
can only react with the TYR enzyme associated with the liposomes surface. All in all, these results 
confirm the preserved activity of the microreactors and that ~40% of the enzyme is entrapped 
within intact liposomes.
3.3.2. Repeated Enzymatic Conversion. We,35,36,45 and others,56 have previously demonstrated that 
microreactors based on a polymer carrier shell encapsulating liposomes are able to handle 
successive enzymatic reactions within their liposomal subunits. This is a crucial aspect, since it is 
expected that, once administered into the body, the microreactors will able to convert molecules 
in a continuous and sustained manner. Enzymes are not only challenging and costly to obtain in a 
highly-purified form suitable for human use but it is also advantageous for patients’ compliance 
to minimize the amount of doses to be administered. As such, to confirm that the TYR enzyme 
within MR3LTYR could be reused, we repeated the enzymatic conversion by exchanging the 
melanin product by fresh DMEM over multiple rounds. The results, which were normalized to the 
absorbance reading at 475 nm monitored after the initial reaction at 37 ℃, showed that the 
enzymatic conversion was reduced by 10%, 50% and 60% between each subsequent cycle, 
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respectively (Figure 6bi). Nonetheless, it was still possible to measure enzymatic activity even 
after four cycles of enzymatic reaction. This shows MR3LTYR to be a robust platform able to 
conduct several reaction cycles, even after being exposed to spinning and resuspension treatment 
for multiple rounds. Figure 6bii shows that, although slightly aggregated, MR3LTYR preserve their 
structural integrity after the four rounds of spinning/resuspension.
3.4. Microreactors Interaction with Melanoma Cells. Biocompatibility of microreactors 
consisting of a polymeric shell entrapping thousands of liposomes has been previously reported 
by several research groups including ours in several cell lines.35,36,45,48,57  Since, in order to deplete 
L-tyr from the intra-tumor environment, MR3LTYR will have to avoid cell internalization, we 
assessed the interaction of pristine MR3L in terms of cell viability (CV) and cell internalization 
by the mouse melanoma cell line B16-F10 and macrophage RAW 264.7 cell lines. The mouse 
macrophage RAW 264.7 cell line was chosen due to the relevance of macrophages as the first 
defense line of the human body against invading microorganisms. Macrophages will be also 
circulating in the blood vessels at the melanoma tumor site.
3.4.1. Microreactors Biocompatibility. We first evaluated the CV of both B16-F10 and RAW 
264.7 cells exposed to empty MR3L at two different microreactors-to-cell ratios (50:1 and 100:1) 
for up to five days. The CV readings, which were normalized to untreated cells (nCV), showed 
that no significant decrease in nCV for B16-F10 for neither 50:1 or 100:1 microreactors-to-cell 
ratios at all the studied time-points (Figure S6a, Supporting Information). In contrast, a significant 
decrease in nCV was observed when RAW 264.7 cells were exposed to a 100:1 microreactors-to-
cell ratio for all the studied time-points (Figure S6b, Supporting Information). Thus, to avoid any 
potential cytotoxicity, we decided to conduct the following experiments employing a 50:1 
microreactors-to-cell ratio. 
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3.4.2. Microreactors Association with Melanoma Cells. The assembly of microreactors with 
demonstrated activity in a test tube has impressively advanced and, in recent years, many examples 
of progressive functionality have been reported as recently reviewed.21–23,58 However, it has been 
only recently that the interaction of such microreactors with cells has started to be explored. A first 
approach was reported by Hammond and co-workers by co-culturing microbeads and insulin-
secreting pancreatic β-cells to enhance the cells function and survival.59 Further progress in the 
field has been conducted by Städler and co-workers by illustrating the ability of extracellular 
microreactors to remove reactive oxygen species in the presence of damaged hepatocytes46 or 
neuroblastoma cells.60 
We assessed the integration of MR3LTYR into melanoma cells by confocal laser scanning 
microscopy (CLSM) (Figure 7). In order to image the microreactors, fluorescently labelled PAH 
(PAHF) was used for the MR3LTYR assembly (MR3LTYR-PAHF). The MR3LTYR-PAHF were then 
incubated with B16-F10 melanoma cells for up to five days. After the different incubation times, 
the cells were fixed, their actin filaments stained and imaged by CLSM. As expected, due to their 
large size (~5-6 µm in diameter), the MR3LTYR-PAHF (green fluorescence signal) were not 
internalized by the melanoma cells (red fluorescence signal) (Figure 7b). Importantly, and as 
previously shown by the CV assays, healthy looking melanoma cells could be observed at all the 
studied time-points. We also assessed the integrity of the liposomal compartments at different 
time-points for the whole five-day period. To this end, the microreactors were fabricated 
employing LFTYR yielding MR3LFTYR. After the different incubation times, the cells were stained, 
fixed and visualized by CLSM. Upon incubating MR3LFTYR for one to three days, homogeneously 
distributed green fluorescence signal along the microreactors shell could be observed (Figure 7c). 
Those results potentially indicate a relatively stable liposome membrane protecting the entrapped 
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enzyme. In contrast, after four and five days of incubation, the green fluorescence signal was 
distributed throughout the microreactors. This suggests either the leakage of the fluorescent lipid 
form LFTYR or LFTYR fusion or rearrangement.61 Since liposomes integrity is a central factor for the 
microreactors performance, MR3LFTYR functionality in the presence of melanoma cells will be 
assessed for up to three days. 
3.5. Microreactors Activity to Inhibit Melanoma Cells Proliferation. To evaluate the potential 
of the as-prepared microreactors towards melanoma treatment, we next examined the ability of 
MR3LTYR in inhibiting B16-F10 melanoma cell growth in culture. We incubated B16-F10 
melanoma cells with MR3LTYR and free TYR and monitored the nCV after 1, 2 and 3 days, 
respectively (Figure 8). When incubating the cells with same units of TYR as encapsulated within 
the MR3LTYR but in its free form, only a ~20% decrease in nCV was observed for the three time-
points. However, the results were different for cells incubated with MR3LTYR. While only ~10% 
decrease in nCV was observed after 1 day; 2 and 3 days of incubation decreased the nCV by ~35 
and ~50%, respectively. The different results obtained for the free TYR and TYR within MR3LTYR 
could be explained by the fast degradation of the TYR enzyme by proteases of the cell medium. 
This highlights the importance of an encapsulation platform to protect the enzyme, which is an 
important fact for our envisioned application, since proteases are implicated in tumor progression, 
angiogenesis, invasion and metastasis.39,62 The decrease in nCV when employing microreactors 
suggest that MR3LTYR, by means of their semipermeable nature, are able to deplete L-tyr. Next, 
we also evaluated the effect of both free TYR and MR3LTYR on the nCV of RAW 264.7 (a model 
non-L-tyr-dependent cell line). Figure 8b shows a significant decrease in nCV upon incubating 
both the free TYR and MR3LTYR with RAW 264.7 cells for all three time-points. However, this 
decrease in nCV was lower (~20% decrease in nCV for the all the time-points) as compared to the 
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decrease in nCV for B16-F10 cells (~35% and ~50% decrease for two and three days incubation 
time, respectively). Although in recent years many examples of microreactors conducting 
enzymatic reactions in the presence of cells have been published by us35,36,45 and others,46,48,60,63,64 
this is the first report where the depletion/conversion of a substrate into a product by an enzymatic 
microreactor is translated into anti-tumor properties. 
3.6. Dynamic Intra-tumor Environment. Shear stress can influence important parameters such 
as the biocompatibility65 or cell interaction66 of a given carrier however, evaluating the effect of 
shear stress when characterizing a novel delivery system is often omitted. This fact could partly 
explain the deficient translation from in vitro static studies to in vivo models.67 Cancer cells also 
sense shear stress forces created by both the blood flow from the neighboring vascular 
microenvironment (with values ranging from 0.5 to 30.0 dyn cm-2) as well as the interstitial flow 
(with values as low as 0.1 dyn cm-2).68,69 However, studies about the impact of shear stress on the 
carriers interaction with cancer cells remain scarce.70 Herein, to better resemble the physiological 
environment that the microreactors will encounter in the tumor site, the ability of MR3LTYR to 
prevent melanoma cells progression through L-tyr depletion was studied under the effect of two 
physiologically relevant shear stresses (τ = 0.5 dyn cm-2 (τ0.5) and τ = 20.0 dyn cm-2 (τ20)). We 
compared the results to the previously reported static conditions (τ0). As such, we assessed the 
nCV of B16-F10 melanoma cells upon incubation with MR3LTYR and free TYR by means of a 
microfluidic setup (Figure 9a). Both τ0.5 and τ20 were applied over the micro-channels. Figure 
9b shows nCV readings upon incubation of MR3LTYR at τ0.5 for one, two and three days (Figure 
9 shows only the most relevant statistics, complete list of statistics can be found in Figure S7, 
Supporting Information). As controls, cells only, free TYR and empty MR3L were considered. As 
expected,66 neither τ0.5 nor τ20 did have a detrimental effect on nCV (Figure S8, Supporting 
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Information). While, at τ0.5, the free TYR did not produce a significant decrease in nCV, at τ20 a 
~10% decrease in nCV was observed for free TYR at all the studied time points (Figure 9b and c). 
The higher values of nCV for free TYR at both τ0.5 and τ20 as compared to τ0, can be expected 
by the fact that the volume of medium in the microfluidic system (6 mL) is higher than the 
medium added in each well during static conditions (200 µL). Importantly, this fact does not 
affect the MR3LTYR since they remain associated with the cells due to their large size. In contrast, 
free TYR has been highly diluted in the microfluidic set up, thus reducing its ability to deplete L-
tyr. Interestingly, no significant differences in the decrease in nCV can be observed when 
incubating MR3LTYR at τ0.5 and τ20 as compared to τ0. This results are of utmost interest since, 
as previously stated, the volume of medium in the microfluidic system is ~30 times higher than 
the medium added in each well during static conditions. Thus, although the L-tyr concentration is 
the same for dynamic and for static conditions, the total L-tyr amount is ~30 times higher for 
dynamic conditions. Therefore, those results highlight the enormous potential of MR3LTYR to 
deplete L-tyr even at very high amounts, which is translated in a significant reduction in nCV for 
melanoma cells.
Finally, to verify that the MR3LTYR microreactors were not internalized by cells and also, as an 
attempt to assess their integrity after the shear stress conditions, we assembled microreactors 
employing either PAHF to create MR3LTYR-PAHF or LFTYR yielding MR3LFTYR, respectively. After 
incubation of MR3LTYR-PAHF for three days at either τ0.5 or τ20, the cells were stained, fixed and 
visualized by CLSM. Figure 10 a and b depict healthy looking melanoma cells after the shear 
stress conditions and upon being in contact with MR3LTYR. When incubating MR3LFTYR at either 
τ0.5 or τ20 for 3 days, the green fluorescence signal arising from LFTYR was distributed throughout 
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the microreactor indicating a potential leakage of the fluorescent lipid of fusion and rearrangement 
among the different LFTYR (Figure 10c). 
4. CONCLUSION
To sum up, we have shown that liposome-containing microreactors are able to conduct enzymatic 
conversions in the presence of cells and under the effect of shear stresses resembling the dynamic 
environment of the tumour site. The depletion of the amino acid L-tyrosine by the microreactors 
inhibits melanoma cell growth in vitro. The results, therefore, represent an important step in the 
microreactors field since we have moved on from model enzymes to a medically relevant condition, 
i.e., slowing down melanoma progression. Further developments will include the assembly of 
microreactors with stabilized liposomes that can perform for extended periods of time (i.e., more 
than three days) and also with higher enzyme encapsulation efficiencies. Such stabilization could 
be performed either by coating the liposomes with polymer layers or by replacing them by 
polymersomes. Additionally, this multicompartment carrier will allow for the combination of 
enzyme therapy together with the co-encapsulation of small anti-tumour compounds to be loaded 
either in the liposomes or in the PLGA core.
Although many challenges still remain to be addressed, and the field of microreactors in 
biomedicine is still in its infancy, these highly advanced microreactors with multiple compartments 
may propose an alternative for future biomedical technologies.  
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FIGURES
Scheme 1. Schematic illustration of the microreactors assembly. The assembly starts by a 
poly(D,L-lactic-co-glycolic acid) (PLGA) microsphere (i) coated by a poly(allylamine 
hydrochloride) (PAH) polymer precursor layer (ii) that allows for the deposition of tyrosinase 
(TYR)-loaded liposomes (LTYR). To allow for the deposition of another LTYR layer, a PAH 
separation layer is needed (iii). After a maximum of three LTYR deposition steps, the polymer 
carrier shell is constructed by the alternating deposition of poly(styrenesulfonic acid) (PSS) and 
PAH (iv). The assembly is terminated by a PSS layer and microreactors loaded with the TYR 
enzyme are obtained. a) The substrate L-tyrosine (L-tyr) is able to permeate through the liposomes 
membrane, interact with the encapsulated TYR enzyme and be converted into melanin by means 
of several intermediate products. b) The potential of the as-prepared microreactors to inhibit 
melanoma cells progression is evaluated in a microfluidic set up under the influence of intra-tumor 
shear stress. 
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Figure 1. Enzyme encapsulation within liposomes. a) Liposomes encapsulating different amounts 
of tyrosinase (TYR) are destroyed by adding Triton X and the experimental concentration of TYR 
is assessed by a bicinchoninic acid (BCA) assay. The encapsulation efficiency (EE) of the 
liposomes encapsulating the highest TYR amount is calculated. b) The diameter and polydispersity 
(PDI) of liposomes encapsulating different amounts of TYR is determined by dynamic light 
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scattering measurements. c) Zeta ()-potential measurements of liposomes loaded with increasing 
amounts of TYR. d) Normalized absorbance (nAbsorbance) readings measuring the conversion of 
L-tyrosine (L-tyr) into melanin by TYR encapsulated within liposomes at two different 
temperatures.  
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Scheme 2. Schematic illustration of tyrosinase (TYR)-loaded microreactors including the 
chemical structures of the relevant compounds. Micron-sized poly(D,L-lactide-co-glycolide) 
(PLGA) microspheres are first coated with poly(allylamine hydrochloride) (PAH) to render a 
positively charged surface that allows for the deposition of TYR-loaded liposomes (LTYR). To 
allow for the deposition of a second and a third LTYR layers, a separation PAH layer is needed. 
Following on, the carrier shell is assembled by the subsequent adsorption of poly(styrene 
sulfonate) (PSS) and PAH polymer layers which interact by electrostatics.
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Figure 2. Characterization of the microreactors assembly. a) Zeta ()-potential measurements 
measured after incubating poly(D,L-lactic-co-glycolic acid) (PLGA) microspheres with increasing 
amounts of poly(allylamine hydrochloride) (PAH) over time. b) -potential of the PLGA 
microspheres measured after the different polymer and tyrosinase-loaded liposomes (LTYR) coating 
steps. Different concentrations of PAH and poly(styrenesulfonic acid) (PSS) are employed.
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Figure 3. Build-up of tyrosinase (TYR)-loaded liposomes (LTYR) onto poly(D,L-lactic-co-glycolic 
acid) (PLGA) microspheres. Normalized fluorescence intensity (nFI) readings monitored after the 
addition of fluorescently labelled LTYR (LFTYR) onto poly(allylamine hydrochloride) (PAH)-coated 
PLGA microspheres. In between each LFTYR deposition step, a PAH separation layer is required. 
The results have been normalized to the first LFTYR deposition step.
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Figure 4. Microreactors characterization. a) Normalized fluorescence intensity (nFI) readings due 
to the tyrosinase (TYR)-loaded fluorescently labelled liposomes (LFTYR) measured after each 
deposition step for microreactors containing one (i), two (ii), three (iii) and four (iv) LFTYR 
deposition steps. The FI has been normalized (nFI) to the FI reading after the first LFTYR deposition 
step. b) Differential interference contrast (DIC) (left) and fluorescence (right) microscopy images 
of microreactors containing one (i), two (ii), three (iii) and four (iv) LFTYR deposition steps.
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Figure 5. Microreactors characterization by quartz crystal microbalance with dissipation 
monitoring (QCM-D). Change in frequency (Δf) (a) and dissipation (ΔD) (b) of a QCM-D crystal 
after each deposition step.
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Figure 6. Microreactors functionality. The substrate L-tyrosine (L-tyr) is able to permeate through 
the polymer shell and the liposomes membrane to interact with the tyrosinase (TYR) enzyme and 
be converted, by means of several intermediate products, into melanin. a) Enzymatic reaction 
kinetics of microreactors entrapping three layers of TYR-loaded liposomes (LTYR) (MR3LTYR) at 
both 37 ℃ and at room temperature (RT), empty microreactors (MR3L) and free TYR incubated 
in a Dulbecco´s Modified Eagle´s Medium (DMEM) solution containing L-tyr. A solution of 
DMEM only is added as a control. The product is measured by monitoring the absorbance of 
melanin dissolution products at 475 nm. The absorbance readings are normalized to the highest 
absorbance reading (nAbsorbance). b) i) nAbsorbance readings of the enzymatic reaction of 
MR3LTYR for four subsequent rounds. As control, MR3L are considered. The absorbance readings 
have been normalized to the absorbance measurement after the first cycle. ii) Differential 
interference contrast (DIC) microscopy images of MR3LTYR after the four reaction cycles.
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Figure 7. Microreactors integration within melanoma cells. Confocal laser scanning microscopy 
(CLSM) images of melanoma B16-F10 cells only at different time intervals (a). b) CLSM images 
of B16-F10 cells co-cultured with microreactors at different time points. The microreactors are 
encapsulating three layers of tyrosinase (TYR)-loaded liposomes (LTYR) and have been assembled 
with fluorescently labelled poly(allylamine hydrochloride) (PAHF) to render MR3LTYR-PAHF. c) 
CLSM images of B16-F10 cells co-cultured with microreactors at different time intervals. The 
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microreactors have been assembled employing fluorescently labelled LTYR (LFTYR) to render 
MR3LFTYR. Phalloidin-TRITC (red signal) was used to stain the actin filaments of the cells. The 
green fluorescence signal arises either from PAHF or from LFTYR. 
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Figure 8. Microreactors activity in vitro. a) In the presence of cells, the substrate L-tyrosine (L-
tyr) is able to permeate through the polymer shell and the liposomes membrane to interact with the 
tyrosinase (TYR) enzyme and be converted, by means of several intermediate products, into 
melanin. b) Normalized cell viability (nCV) readings of melanoma B16-F10 (left side) and RAW 
264.7 (right side) cells exposed to free TYR enzyme and microreactors for different time intervals. 
The microreactors have been assembled by encapsulating three layers of TYR-loaded liposomes 
(LTYR) to render MR3LTYR.
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Figure 9. Microreactors activity in a microfluidics set up. a) In the presence of cells and upon 
applying shear stress, the substrate L-tyrosine (L-tyr) is able to permeate both through the polymer 
shell and the liposomes membrane to interact with the tyrosinase (TYR) enzyme and be converted, 
by means of several intermediate products, into melanin. b) Normalized cell viability (nCV) 
readings of melanoma B16-F10 cells exposed to microreactors in static conditions (τ0) and 
exposed to both free TYR and microreactors at shear stress conditions (τ = 0.5 dyn cm-2, τ0.5) for 
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different time intervals. The microreactors are encapsulating three layers of TYR-loaded 
liposomes (LTYR) to render MR3LTYR. c)  nCV readings of melanoma B16-F10 cells exposed to 
MR3LTYR at τ0 and to free TYR and MR3LTYR at shear stress conditions (τ = 20 dyn cm-2, τ20) 
for different time intervals. 
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Figure 10. Microreactors integration in a microfluidics set up. Confocal laser scanning microscopy 
(CLSM) images of melanoma B16-F10 cells only (a) and co-cultured with: b) MR3LTYR-PAHF 
microreactors consisting of carriers encapsulating three layers of tyrosinase (TYR)-loaded 
liposomes (LTYR) and assembled with fluorescently labelled poly(allylamine hydrochloride) 
(PAHF) or c) MR3LFTYR microreactors consisting of carriers encapsulating fluorescently labelled 
LTYR (LFTYR) for different time intervals under the effect of two intra-tumour mimicking shear 
stresses (τ = 0.5 dyn cm-2 (τ0.5) and τ = 20 dyn cm-2 (τ20)). Phalloidin-TRITC (red signal) was 
used to stain the actin filaments of the cells while the green fluorescence signal results from either 
fluorescently-labelled PAHF or LFTYR. 
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of L-tyrosine into melanin by the enzyme tyrosinase at different temperatures, determination of the 
encapsulation efficiency of the tyrosinase enzyme within the liposomes, characterization of 
poly(D,L-lactide-co-glycolide) microspheres, cell viability of empty microreactors at two different 
microreactors-to-cell ratios (50:1 and 100:1) for B16-F10 melanoma and RAW 264.7 cells, cell 
viability of B16-F10 melanoma cells exposed to free tyrosinase enzyme in static and shear stress 
conditions and cell viability of  B16-F10 melanoma cells exposed to empty microreactors under 
shear stress conditions. ζ-potential measurements of the whole assembly.
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